<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569686</url>
  </required_header>
  <id_info>
    <org_study_id>13107</org_study_id>
    <nct_id>NCT00569686</nct_id>
  </id_info>
  <brief_title>Lovaza Therapy of Peripheral Arterial Disease</brief_title>
  <official_title>Lovaza Therapy of Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reliant Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sixty patients with mild-to-moderate PAD (ABI 0.4-0.9) and hypertriglyceridemia (&gt;200 mg/dl)
      already treated with statins will be imaged at baseline and randomized to Lovaza and placebo
      for 12 months. MR imaging will be repeated at the end of the 12-month period.

      We hypothesize that treatment of hypertriglyceridemia in patients with PAD with Lovaza will
      reduce atherosclerotic plaque volume in the superficial femoral artery (SFA) by 2% over 1
      year compared to placebo. Secondary aims will be to show improved plaque characteristics
      (thickened fibrous cap, reduced lipid-rich necrotic core, improved exercise calf muscle
      perfusion using first-pass contrast enhanced MRI and improved exercise treadmill performance
      with Lovaza compared to matching placebo.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subject meeting criteria
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">February 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment of hypertriglyceridemia in patients with PAD with Lovaza will reduce or prevent progression of atherosclerotic plaque volume in the superficial femoral artery (SFA) by 2% over 1 year as compared to placebo.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>show improved plaque characteristics, improved exercise calf muscle perfusion using first-pass contrast enhanced MRI and improved</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with lovaza</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lovaza</intervention_name>
    <description>lovaza 4 gm po daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, any ethnicity, ages 55-75

          -  Mild to moderate PAD (ankle brachial index (ABI) of 0.4-0.9 in either or both limbs)

          -  Symptomatic intermittent claudication in either or both limbs

          -  Hyperlipidemia treated with HMG-CoA reductase inhibition with persistent
             hypertriglyceridemia (triglycerides&gt;200).

        Exclusion Criteria:

          -  Patients with critical limb ischemia

          -  Moderate to severe chronic kidney disease (requiring hemodialysis or glomerular
             filtration rate (GFR) &lt; 45 ml/min)

          -  Contraindication to MRI (pacemakers, defibrillators, intraocular metal, certain
             intracerebral aneurysm clips, etc.)

          -  Claustrophobia

          -  Known allergy to gadolinium chelates

          -  Patients with iron storage disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Kramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2007</study_first_submitted>
  <study_first_submitted_qc>December 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>peripheral artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

